BMRN BioMarin Pharmaceutical
$56.22 -2.29%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-2.29%
YTD
+2.80%
P/E
152.93
P/B
1.88
ROE
1.2%
Div yield
—
Beta
0.39
Market cap
$11.2B
RSI (14)
26
Next earnings
Oct 26, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$57.54
Close
$56.22
VWAP (n/a)
—
Day high
$57.88
Day low
$55.76
Volume
3.7M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
BioMarin Appoints Cara Bauer as Chief People Officer
Yahoo Finance · Oct 5
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Yahoo Finance · Oct 2
The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)
Yahoo Finance · Oct 1
BioMarin and Profluent partner on AI-designed enzyme therapies
Yahoo Finance · Oct 1
Profluent Partners With BioMarin to Design Novel Medicines Using AI
Yahoo Finance · Sep 30
3 Healthcare Stocks That Fall Short
Yahoo Finance · Sep 28
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Oct 6, 2026 View → 8-K Sep 30, 2026 View → 8-K Sep 15, 2026 View → 8-K Sep 14, 2026 View → 8-K Sep 1, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell BMRN. Try it in the Lab to size a position and see the risk.